# Tirzepatide: research overview — Zap Peptides > Tirzepatide is an FDA-approved GIP/GLP-1 dual agonist. SURMOUNT-1: −20.9% body weight versus −3.1% placebo at 72 weeks. SURPASS-2: superior HbA1c vs. another incretin. Zap Peptides. The first dual GIP and GLP-1 receptor agonist, FDA-approved for type 2 diabetes and obesity — with a Phase 3 efficacy dataset covering more than 4,000 randomised participants. ## The short version Tirzepatide is a 39-amino-acid synthetic peptide that activates two incretin receptors simultaneously: the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R). It is a prescription drug, FDA-approved since May 2022 for type 2 diabetes and subsequently for obesity and sleep apnea. It is not a research-only compound — it is an approved medicine dispensed through the normal prescription system [9]. The efficacy numbers are large by the standards of obesity pharmacology. SURMOUNT-1, a 2,539-person Phase 3 RCT, recorded a mean weight change of −20.9% at the 15 mg dose versus −3.1% with placebo at 72 weeks [11]. A head-to-head Phase 3b trial (SURMOUNT-5, n=751) recorded −20.2% versus −13.7% with another incretin at 72 weeks [8]. In type 2 diabetes, SURPASS-2 (n=1,879) showed superior HbA1c reduction and greater weight loss versus another approved incretin at every dose tested [12]. Gastrointestinal side effects — nausea, vomiting, diarrhea, constipation — are the main dose-limiting adverse events and occur most during dose escalation [11]. The prescribing label carries a boxed warning regarding medullary thyroid carcinoma based on rodent data [9]. This desk does not recommend this or any other drug. ## What it is Tirzepatide is a 39-amino-acid linear synthetic peptide based on the native GIP sequence. A C20 fatty diacid (eicosanedioic acid) moiety is attached via a glutamic acid linker and two AEEA spacers to a lysine side chain; this fatty-diacid arm confers high albumin affinity and extends the plasma half-life to approximately five days, enabling once-weekly subcutaneous injection. Molecular formula: C225H348N48O68. It was developed as the first member of the "twincretin" pharmacological class — a single molecule that co-activates both major incretin receptors — and was approved under the international nonproprietary name *tirzepatide*. Per the brand-name avoidance rules on this desk, trademark names are not used. The prescribing information classifies it as a GIP/GLP-1 receptor agonist (RA), not a GLP-1 RA alone [9]. FDA approvals as of the reference literature: type 2 diabetes mellitus (May 2022); chronic weight management in adults with obesity or overweight plus a weight-related condition (November 2023); moderate-to-severe obstructive sleep apnea in adults with obesity. All approved formulations are prescription-only [9]. ## How it works Tirzepatide engages both the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) with a single molecule, producing a combined incretin effect that exceeds what selective GLP-1 receptor agonism achieves alone [9]. **GLP-1 receptor activation** suppresses glucagon, slows gastric emptying, and reduces appetite and food intake — the same mechanism as the earlier incretin class. **GIP receptor activation** enhances glucose-dependent insulin secretion (particularly postprandial), and at the adipocyte level appears to shift energy storage dynamics. The combination of both pathways is thought to explain why the dual agonist produces larger glycaemic and body-weight reductions than selective GLP-1 receptor agonism in head-to-head comparisons [8][12]. Gastric emptying is transiently slowed, with the effect attenuating over continued dosing [9]. This mechanism underlies both the appetite suppression and several of the safety considerations — including the perioperative aspiration concern and the interaction with oral contraceptive absorption. ## What the research shows The tirzepatide clinical dataset is among the largest and most rigorous for any incretin-class agent. Key trials: **SURMOUNT-1 (2022):** 2,539 adults with obesity (BMI ≥30, or ≥27 with a weight-related complication) without diabetes; 72-week Phase 3 double-blind RCT. Mean weight changes: −15.0% (5 mg), −19.5% (10 mg), −20.9% (15 mg) versus −3.1% placebo. Most common adverse events were gastrointestinal, mostly mild to moderate, occurring primarily during dose escalation [11]. **SURPASS-2 (2021):** 1,879 adults with type 2 diabetes; 40-week open-label Phase 3 trial. HbA1c reduction: 2.01–2.30 percentage points (tirzepatide 5–15 mg) versus 1.86 pp with another approved once-weekly incretin at 1 mg. Body weight reductions were 1.9–5.5 kg greater with tirzepatide at all doses [12]. **SURMOUNT-5 (2025):** 751 adults with obesity without type 2 diabetes; 72-week Phase 3b open-label head-to-head. Tirzepatide (maximum tolerated dose of 10 or 15 mg) versus another approved incretin at maximum tolerated dose. Least-squares mean weight change: −20.2% vs −13.7% (P<0.001) [8]. **Safety meta-analysis (2023):** Systematic review and meta-analysis of 9 RCTs (9,871 participants). Pancreatitis: RR 1.46, 95% CI 0.59–3.61 (not statistically significant). Composite gallbladder or biliary disease: **RR 1.97, 95% CI 1.14–3.42** (statistically significant versus controls) [10]. **Evidence tier:** Large Phase 3 RCTs, active head-to-head comparisons, and systematic reviews. The efficacy evidence is high quality; the safety dataset is large but ongoing post-marketing surveillance continues. ## Reported effects, cautions & safety The following patient-reported experiences are **anecdotal, not clinical evidence**. They are drawn from structured exit interviews and post-market community accounts and are included because they reflect how the clinical pharmacology manifests in practice. **Frequently reported benefits (anecdotal, not clinical):** - *Appetite suppression / quieter food noise*: dramatically reduced intrusive food-related thoughts; reported by 79–91% of participants in SURMOUNT exit interviews as a top benefit. - *Increased energy*: 62–79% of interview participants described feeling more energetic as weight declined; early fatigue during dose escalation is also reported. - *Improved mood and self-confidence*: 47–55% in structured exit interviews; psychiatric case reports document mood improvement alongside weight loss. - *Improved sleep quality*: some patients describe better sleep onset and depth, and reduction in sleep-apnea symptoms. **Frequently reported side effects (anecdotal, not clinical):** - *Nausea* (~25–50% of community reports): typically peaks in the first 1–2 weeks of each dose increase. - *Constipation and/or diarrhea* (15–25% each): often cycling between the two, tied to slowed gastric emptying. - *Injection-site reactions*: second most frequent FAERS category (>19,000 reports, 2022–2025) — redness, tenderness, small lumps, typically resolving within 2–5 days. - *Hair thinning (telogen effluvium)*: ~4–5% in clinical trials versus ~1% placebo; attributed to rapid weight loss, typically self-limiting. **Published safety cautions:** Gastrointestinal intolerance is the dominant adverse-effect class, dose-related, and causes most discontinuations [11]. The FDA label carries a **boxed warning** regarding thyroid C-cell (medullary) tumours based on rodent data; the compound is contraindicated in persons with personal or family history of medullary thyroid carcinoma or MEN-2 — this is a label-mandated contraindication based on animal data, not a confirmed human outcome [9]. Gallbladder and biliary disease showed a statistically significant increase (composite RR 1.97) in the 9-trial meta-analysis; pancreatitis was not significantly increased [10]. Lean mass represents approximately 25% of lost weight based on DXA substudies. Weight regain follows discontinuation, framing this as a chronic therapy rather than a short course. Hypoglycaemia risk increases when combined with insulin or sulfonylureas [9]. Delayed gastric emptying may reduce oral contraceptive reliability around dose increases [9]. **WADA status:** Not specifically prohibited under the WADA Prohibited List. It is an FDA-approved prescription drug. ## Where it fits in the metabolic picture Tirzepatide is the clinical anchor of this desk — the compound with Phase 3 human data at the scale needed to quantify both efficacy and safety with confidence. Among the three molecules reviewed here, it is the only one with an FDA-approved indication and a large peer-reviewed efficacy record. For the researcher reading this desk in the context of body recomposition, the tirzepatide literature provides a useful benchmark: −20.9% body weight at 72 weeks in a well-powered RCT [11] sets a performance ceiling against which other metabolic agents — including AOD-9604's null human result and MOTS-c's entirely preclinical data — can be calibrated. Its mechanism (dual incretin receptor agonism) operates upstream of fat cells — reducing the energy surplus that drives adipogenesis — rather than acting directly on adipocyte lipase or mitochondrial bioenergetics the way [AOD-9604](/aod-9604) or [MOTS-c](/mots-c) are proposed to do. --- A numerically honest digest of the published evidence — effect sizes, study designs, and the gaps between them.